MELBOURNE, AUSTRALIA--(Marketwired - Oct 15, 2013) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) wishes to inform the Market that Chief Executive Officer, Ms. Alison Mew, will be stepping aside from her day-to-day responsibilities for a period of three months commencing October 15, 2013. She is taking this step for personal, health-related reasons.

During the period of her absence, Mr. Tom Howitt will assume the role of Acting CEO alongside his current duties as the Company's CFO. Tom has been with Genetic Technologies for more than nine years and has a wealth of experience to steer the Company through this period. He will be assisted in this by the Chairman, Dr. Mal Brandon, and external advisors in specific technical and commercial aspects of the healthcare business.

We are confident that this arrangement will ensure the Company will continue to meet the milestones and achieve success in building its molecular testing and diagnostics business. We look forward to Alison's return to the CEO role in early 2014.

About Genetic Technologies Limited
Genetic Technologies is an established diagnostics company with more than 20 years of experience in commercializing genetic testing, non-coding DNA and product patenting. The Company has operations in Australia and the U.S. and is dual-listed on the ASX (Code: GTG) and NASDAQ (Ticker: GENE). Genetic Technologies is focused on the commercialization of its patent portfolio through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics assets. Its U.S. subsidiary, Phenogen Sciences Inc., offers novel predictive testing and assessment tools to help physicians proactively manage women's health. Phenogen's lead product, BREVAGen™, is a first in class, clinically validated risk assessment test for non-familial breast cancer.

For more information, please visit and

Safe Harbor Statement
Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.

Contact Information:


Tom Howitt
Chief Executive Officer (Acting)
Genetic Technologies Limited
Phone: +61 3 8412 7000

Laura Forman (USA)
Blueprint Life Science Group
+1 (415) 375 3340, Ext. 103